- Nachrichtendetail
-
28.05.2024 12:50:11 - dpa-AFX: *MERCK SAYS PHASE 3 KEYNOTE-522 TRIAL OF KEYTRUDA IN COMBINATION WITH CHEMOTHERAPY MEETS OVERALL SURVIVAL ENDPOINT
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
Merck & Co | A0YD8Q | NYSE | 131,500 | 26.06.24 22:00:38 | -1,420 | -1,07% | 131,500 | 132,450 | 133,140 | 132,920 |
